2-乙基-5-甲基苯并呋喃 | 17133-95-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 2-乙基-5-甲基苯并呋喃
• 英文名称: 5-methyl-2-ethylbenzofuran
• 英文别名: 2-ethyl-5-methylbenzofuran；2-ethyl-5-methylbenzo[b]furan；2-ethyl-5-methyl-1-benzofuran
• CAS: 17133-95-8
• 化学式: C₁₁H₁₂O
• mdl: MFCD11044831
• 分子量: 160.216
• InChiKey: GQHVHQOJJFDUKW-UHFFFAOYSA-N

物化性质

• 沸点：
  237 °C
• 密度：
  1.030
• 闪点：
  95 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  2-乙基-5-甲基苯并呋喃 生成 2-Ethyl-3-formyl-5-methylbenzofuran
  参考文献：
  名称：

  NEIDLEIN R.; BERNHARD E., ARCH. PHARM., 1978, 311, NO 8, 714-718

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(2,2-二乙氧基乙氧基)甲苯 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 18.0h， 生成 2-乙基-5-甲基苯并呋喃
  参考文献：
  名称：

  通过级联催化对苯并呋喃进行对映和非对映选择性完全氢化

  摘要：

  我们报道了多取代苯并呋喃在一锅级联催化中的对映和非对映选择性完全氢化。开发的协议有助于受控安装多达六个新定义的立体中心，并产生结构复杂的八氢苯并呋喃，普遍存在于许多生物活性分子中。手性均相钌-N-杂环卡宾络合物和来自络合物前体的原位活化铑催化剂的独特匹配依次作用以实现所提出的过程。

  DOI：

  10.1002/anie.202103910

文献信息

• Npy antagonists, preparation and uses
  申请人：Botez Iuliana

  公开号：US20090233910A1

  公开（公告）日：2009-09-17

  The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

  本发明涉及新颖化合物，它们的制备和用途，特别是在治疗方面的用途。更具体地说，它涉及至少具有两个芳香环的衍生化合物，它们的制备和用途，特别是在人类或动物健康领域。这些化合物对存在于中枢和外周神经系统中的神经肽Y（NPY）的生物受体具有亲和力。本发明的化合物优选为NPY拮抗剂，更具体地说是NPY Y1亚型的拮抗剂，因此可用于治疗或预防涉及NPY的任何疾病。本发明还涉及含有所述化合物的药物组合物，其制备和用途，以及使用所述化合物的治疗方法。
• [EN] S1P RECEPTORS MODULATORS AND THEIR USE THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P ET LEUR UTILISATION
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010043000A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  这项发明涉及具有S1P受体调节活性的新化合物。此外，该发明涉及包括本发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如自身免疫反应。该发明的另一个方面涉及使用包括本发明中至少一种化合物的药物制造药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如自身免疫反应。
• Certain pharmaceutical sulfamoylbenzoyl benzofurans, benzothiophenes,
  申请人：Hoechst Aktiengesellschaft

  公开号：US04156732A1

  公开（公告）日：1979-05-29

  Heterocyclic sulfamoyl-aryl-ketones wherein the heterocyclic component consists of a benzofuran, indole or benzothiophene radical and the sulfamoyl-aryl moiety is ortho-substituted by halogen, methyl or trifluoromethyl having uricosuric, hypouricemic and salidiuretic action and a process for their manufacture.

  含有杂环磺胺基芳基酮的化合物，其中杂环组分由苯并呋喃、吲哚或苯并噻吩基团组成，磺胺基芳基部分被卤素、甲基或三氟甲基邻位取代，具有利尿、降尿酸和尿酸排泄作用，并提供其制备方法。
• <i>cis</i>-Oxypalladation Complexes Derived from (1<i>R</i>,5<i>R</i>)-2(10),3-Pinadiene and Their Utilization in Pd(II)-catalyzed Enantioselective Cyclization of 2-(<i>trans</i>-2-Butenyl)phenols
  作者：Takahiro Hosokawa、Yasushi Imada、Shun-Ichi Murahashi

  DOI：10.1246/bcsj.58.3282

  日期：1985.11

  (1R,5R)-2(10),3-Pinadiene, when treated with either Na2PdCl4 in MeOH or Pd(OAc)2 in AcOH and NaCl, gives di-μ-chloro-bis[(3,2,10-η-cis-4-methoxy or acetoxypinene)palladium(II)] (4a) or (4b), respec...

  (1R,5R)-2(10),3-Pinadiene，当用 MeOH 中的 Na2PdCl4 或 AcOH 和 NaCl 中的 Pd(OAc)2 处理时，得到二-μ-氯-双 [(3,2,10-η -顺-4-甲氧基或乙酰氧基蒎烯）钯（II）]（4a）或（4b），分别...
• TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
  申请人：Everett Steven Albert

  公开号：US20120190639A1

  公开（公告）日：2012-07-26

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  本发明涉及新型化合物，用于治疗或预防癌症和其他增生性疾病，例如其细胞表达细胞色素P450 1B1（CYP1B1）及其等位基因变异的疾病。本发明还提供了含有一种或多种这样的化合物的制药组合物，用于医学治疗，例如治疗癌症或其他增生性疾病的预防或治疗，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。本发明还提供用于鉴定用于治疗或预防表达CYP1B1及其等位基因变异的细胞的癌症和其他增生性疾病的新型化合物的方法。本发明还提供了一种用于确定本发明的化合物在治疗癌症方面的功效的方法。